Skip to search formSkip to main contentSkip to account menu

sampatrilat

Known as: N-(1-(2-carboxy-3-(N(2)-mesyllysylamino)propyl)-1-cyclopentylcarbonyl)tyrosine 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (3)

MesylatesProtease InhibitorsTyrosine

Narrower (1)

UK 81,252
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin—Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme
Neprilysin (NEP) and angiotensin-converting enzyme (ACE) are two key zinc-dependent metallopeptidases in the natriuretic peptide… 
2020
2020
Whey-Derived Peptides Interactions with ACE by Molecular Docking as a Potential Predictive Tool of Natural ACE Inhibitors
Several milk/whey derived peptides possess high in vitro angiotensin I-converting enzyme (ACE) inhibitory activity. However, in… 
2018
2018
Crystal structures of sampatrilat and sampatrilat‐Asp in complex with human ACE – a molecular basis for domain selectivity
Angiotensin‐1‐converting enzyme (ACE) is a zinc metallopeptidase that consists of two homologous catalytic domains (known as nACE… 
2016
2016
The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme
Sampatrilat is a vasopeptidase inhibitor that inhibits both angiotensin I-converting enzyme (ACE) and neutral endopeptidase. ACE… 
2003
2003
Beneficial Effects of Sampatrilat, a Novel Vasopeptidase Inhibitor, on Cardiac Remodeling and Function of Rats with Chronic Heart Failure following Left Coronary Artery Ligation
Sampatrilat is a novel vasopeptidase inhibitor that may offer a greater benefit than traditional angiotensin-converting enzyme… 
2002
2002
Sampatrilat Shire.
  • K. Allikmets
  • Current opinion in investigational drugs
  • 2002
  • Corpus ID: 36238587
Sampatrilat is a dual inhibitor of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE), which is under… 
Highly Cited
1999
Highly Cited
1999
Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects.
1998
1998
Combined inhibition of neutral endopeptidase and angiotensin‐converting enzyme by sampatrilat in essential hypertension
1998
1998
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide…
1996
1996
Renal effects of concurrent E‐24.11 and ACE inhibition in the aorto‐venocaval fistula rat
1 The present studies compare the early renal response to (a) an endopeptidase‐24.11 (E‐24.11) inhibitor (candoxatrilat) (b) an… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License